Membrane Vesicle Influenza Vaccine for Adjuvant-Free Broad Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current influenza vaccines often require multiple doses and adjuvants to provide broad protection against various influenza strains, and there is a need for more efficient and adjuvant-free multivalent vaccines that can elicit a robust immune response.
Innovation Solution
A multivalent influenza virus vaccine (MIV) is developed, comprising a transport protein linked to a multivalent immunogenic polypeptide and a membrane vesicle from genetically modified gram-positive bacteria, which forms a multivalent immunogenic transmembrane polypeptide capable of eliciting an immune response to multiple influenza strains without adjuvant administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current influenza vaccines are used, then broad protection against various influenza strains can be achieved, but multiple doses and adjuvants are required
Solution Approach 1:
The patent combines multiple influenza epitopes (HA, NA, M2e) from different influenza strains into a single multivalent immunogenic polypeptide that is displayed on the surface of membrane vesicles. This merging of multiple antigens into one vaccine formulation eliminates the need for multiple separate doses and adjuvants while maintaining broad protection against various influenza strains.
Solution Approach 2:
The membrane vesicle platform serves multiple functions simultaneously: it acts as a delivery vehicle for the multivalent immunogenic polypeptide, provides inherent adjuvant properties to stimulate immune response, and presents multiple influenza epitopes on its surface. This multi-functionality eliminates the need for separate adjuvant administration and achieves broad protection in a single dose.
2Reliability
If multiple doses and adjuvants are administered, then broad protection is achieved, but vaccine complexity and administration burden increase
Solution Approach 1:
The vaccine combines multiple influenza antigens and adjuvant properties into a single membrane vesicle formulation, reducing the administration burden from multiple separate injections to a single dose while maintaining broad protective efficacy.
3Reliability
If conventional influenza vaccines are used, then immune response can be elicited, but adjuvants are required to enhance effectiveness
Solution Approach 1:
The membrane vesicle platform inherently provides adjuvant properties through its composition and structure, eliminating the need for separate adjuvant administration. The vesicles simultaneously serve as antigen carriers and immune stimulators, reducing complexity while enhancing immune response effectiveness.
Data Source
AI summary
Described herein, are multivalent influenza virus vaccines (MIV), multivalent immunogenic polypeptides (MIP), and fusion proteins. Provided herein are further methods of making and using the MIVs, MIPs, and fusion proteins.